Ala-Hurula V, Myllylä V V, Arvela P, Heikkilä J, Kärki N, Hokkanen E
Eur J Clin Pharmacol. 1979 Feb 19;15(1):51-5. doi: 10.1007/BF00563557.
Plasma ergotamine levels were measured in 33 volunteers (subgroups 11, 12 and 10) after a single dose of ergotamine administered by various routes. Ergotamine tartrate was given in doses normally used in the treatment of acute migraine--2.0 mg orally, 2.0 mg combined with 100 mg caffeine rectally and 0.5 mg i.m. Plasma ergotamine concentrations were determined by radioimmunoassay. The highest and longest lasting levels were found after i.m. administration, the peak concentration being 1.94 +/- 0.34 (SEM) ng/ml at 1/2 h. The corresponding maximum concentrations after oral and rectal administration were 0.36 +/- 0.08 ng/ml at 2 h and 0.42 +/- 0.09 ng/ml at 1 h. In most of the subjects the plasma ergotamine level began to rise again at 24 to 48 h. The cause of the elevation is not known but it might favour possible accumulation of the drug. Absorption from suppositories was at least as good as after oral administration and the former route may therefore be advantageous for migraine patients in whom nausea and vomiting during an attack may prevent efficient oral medication.
对33名志愿者(第11、12和10亚组)通过不同途径单次服用麦角胺后测定其血浆麦角胺水平。酒石酸麦角胺的给药剂量为治疗急性偏头痛的常用剂量——口服2.0毫克、直肠给药2.0毫克并联合100毫克咖啡因、肌肉注射0.5毫克。血浆麦角胺浓度通过放射免疫分析法测定。肌肉注射后血浆麦角胺水平最高且持续时间最长,半小时时的峰值浓度为1.94±0.34(标准误)纳克/毫升。口服和直肠给药后的相应最大浓度分别为2小时时0.36±0.08纳克/毫升和1小时时0.42±0.09纳克/毫升。在大多数受试者中,血浆麦角胺水平在24至48小时时再次开始升高。升高原因不明,但可能有利于药物的蓄积。栓剂的吸收至少与口服给药后相同,因此对于在发作期间恶心和呕吐可能妨碍有效口服给药的偏头痛患者而言,前一种给药途径可能具有优势。